(ISSN 2573-4407)
OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2024): Submission to First Decision: 7.6 weeks; Submission to Acceptance: 13.6 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)
Special Issue
Managing the Psychotic Patient: Pharmacological and Rehabilitative Treatments
Submission Deadline: November 30, 2026 (Open) Submit Now
Guest Editor
Vincenzo Prisco, PhD
Department of Psychiatry ASL Salerno, University Federico II, Naples, Italy
Research Interests: Psychiatric illness management; psychopharmacology; dual diagnosis; drug interactions and side effects
About This Topic
An integrated approach to the treatment of psychosis appears to be the most promising. It includes counseling, case management, hospitalization, rehabilitation, and residential programs, to meet the needs of patients in the acute or subacute phase and with chronic conditions. Psychopharmacological therapy is often used, especially for severe forms. Evidence-based psychotherapeutic approaches are cognitive-behavioral treatments (CBT), with a strong psychoeducational focus. These teach patients problem-solving skills and coping with difficult situations, emphasizing the warning signs, so that the patient can seek medical help before the actual decompensation phase begins. Intervening in the acute phase of a patient diagnosed with psychosis means addressing medical, psychiatric, and sometimes toxicological emergencies, which may include intercurrent illnesses, intoxication, withdrawal symptoms, suicidal behavior, and episodes of violence and impulse control. The presence of severe psychotic, violent, or uncontrolled symptoms requires emergency admission to a psychiatric ward, while treatment for patients with less severe symptoms may be initiated on a day-hospital basis. Long-acting antipsychotics have made an enormous contribution to stabilizing psychotic illness, minimizing side effects.
Keywords
Psychosis; pharmacological treatment; rehabilitative treatment; long-acting antipsychotics
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
- Journal Metrics
-
2024 
CiteScore SJR SNIP 1.2 0.205 0.249 - Newsletter